Vor Biopharma Inc.

Vor Biopharma Inc. held its Annual Meeting of Stockholders, where all three proposals were approved. Stockholders elected Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. as Class II Directors to serve until the 2029 Annual Meeting. Additionally, the Amended and Restated 2021 Equity Incentive Plan was approved, and the selection of Ernst & Young LLP as the independent registered public accounting firm for 2026 was ratified.

Vor Biopharma Inc. announced that its collaborator, RemeGen Co., Ltd., has received conditional approval from China's National Medicinal Products Administration (NMPA) for telitacicept to treat adult patients with IgA nephropathy (IgAN). Additionally, RemeGen received NMPA approval for telitacicept for adult patients with Sjögren's disease in China. These approvals mark significant milestones for telitacicept, a therapy targeting BAFF/APRIL, which Vor Bio is developing globally outside of Greater China.

Vor Bio, a clinical-stage biotechnology company, announced it will provide a corporate update at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 3, 2026, and will be accessible via a live webcast on the company's investor relations website. A replay will be available for about 30 days after the event.

Vor Biopharma reported a significant increase in net loss to $219.6 million for Q1 2026, primarily due to a $188.4 million change in the fair value of warrant liabilities. The company successfully completed a private placement in March 2026, raising $74.9 million, contributing to a strong cash position of $491.5 million, which is expected to fund operations for over one year.

Vor Bio announced that its Compensation Committee granted stock options for 53,400 shares and restricted stock units (RSUs) for 11,350 shares to 6 newly hired employees on May 1, 2026. These grants, totaling 64,750 shares, were made under the 2023 Inducement Plan as material inducements for employment. Both the stock options and RSUs will vest over a four-year period, subject to continued employment.

Vor Biopharma Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Stockholders will vote on the election of two Class II director nominees, the amendment and restatement of the 2021 Equity Incentive Plan, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date for voting is April 15, 2026, with proxy materials available online from April 27, 2026.